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Abstract  
AIM: The aim was to analyze association of Factor V Leiden (G1691A), Factor V R2 (A4070G), and 
Prothrombin (G20210A) Genetic Polymorphism in Macedonian Patients with Occlusive Artery Disease (OAD) 
and Deep Vein Thrombosis (DVT). 
METHODS: Investigated groups consists of 82 healthy, 76 patients with OAD, and 67 patients with DVT. 
Blood samples were collected after written consent, and DNA was isolated from peripheral blood leukocytes. 
Identification of Factor V Leiden (G1691A), Factor V R2 (A4070G), and Prothrombin (G20210A) Genetic 
Polymorphism was done with CVD StripAssay (ViennaLab, Labordiagnostica GmbH, Austria). The population 
genetics analysis package, PyPop, was used for analysis of the data. Pearson's P-values, crude Odds Ratio 
and Wald’s 95% CI were calculated.  
RESULTS: The frequency of G allele for Factor V Leiden was 0.976 for healthy participants, 0.954 for OAD, 
and 0.948 for DVT. The frequency of A allele for Factor R2 is highest in healthy participants (0.951), smaller 
in patients with DVT (0.918), and smallest in the patients with OAD (0.908). G allele frequency for 
prothrombin was 0.976 in healthy participants, 0.980 in patients with OAD, and 0.978 in patients with DVT. 
Test of neutrality (Fnd) showed positive value, but was not significantly different from 0.  Factor V Leiden 
(G1691A), Factor R2 (A4070G), and Prothrombin (G20210A) genotypes in healthy participants and patients 
with OAD and DVT were in Hardy Weinberg proportions. Any association of Factor V Leiden (G1691A), 
Factor R2 (A4070G), and Prothrombin (G20210A) genetic polymorphism with OAD, and DVT in Macedonians 
was not found. 
CONCLUSION: We conclude that significant association of Factor V Leiden (G1691A), Factor R2 (A4070G), 
and Prothrombin (G20210A) genetic polymorphism with occlusive artery disease or deep venous thrombosis 
in Macedonians was not found. 
 
 
 
 
 
Introduction 
  
The association between the inherited gene 
mutations of factor V, prothrombin, and homocysteine 
metabolism and venous thromboembolic events is 
accepted widely, but their influence on the arterial 
circulatory system remains controversial. There are a 
lot of published papers dealing with single or 
combined mutations of factor V, factor V R2, and/or 
prothormbin, but the most important are papers with 
meta-analysis [1-5]. 
Published case-control and cohort studies 
correlating the factor V Leiden, prothrombin (PT) 
G20210A, and methylenetetrahydrofolate reductase 
(MTHFR) C677T (TT genotype) mutations with 
myocardial infarction, ischemic stroke, or peripheral 
vascular disease were included in meta-analysis. The 
association between inherited gene mutations and 
arterial ischemic events was modest. It was found that 
genetic abnormalities specific to factor V, prothrombin, 
and homocysteine metabolism increase the risk for 
myocardial infarction and ischemic stroke, particularly 
among younger patients and women [1].  
Meta-analyses were done of 191 studies in 
relation to factor V G1691A (ie, factor V Leiden), 
factor VII G10976A, prothrombin G20210A, 
plasminogen activator inhibitor-1 (PAI-1) [-675] 
4G/5G, and three platelet glycoprotein (GP) receptor 
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variants (GPIa C807T, GPIbalpha T[-5]C, GPIIIa 
C1565T), involving a total of 66 155 coronary disease 
cases and 91 307 controls. The 1691A variant of the 
factor V gene and the 20210A variant of the 
prothrombin gene, both of which increase circulating 
thrombin generation, might each be moderately 
associated with the risk of coronary disease [2].  
Keijzer et al., 2007 performed a meta-analysis 
to investigate a possible interaction between factor V 
Leiden and hyperhomocysteinemia, including 825 
subjects with venous thrombosis and 2,109 controls, 
for the risk of venous thrombosis [3]. The meta-
analysis yielded no evidence for additive or 
multiplicative interaction between factor V Leiden and 
hyperhomocysteinemia. Both the meta-analyses of 
published studies and a large case-only study did not 
show evidence for interaction between factor V Leiden 
and hyperhomocysteinemia for risk of venous 
thrombosis. 
Another systematic and comprehensive meta-
analysis on all candidate genes to assess their 
genetic contribution to the aetiology of venous 
thromboembolism (VTE) (pulmonary embolism and 
deep venous thrombosis) in all ethnic groups was 
published. Meta-analyses included approximately 126 
525 cases and 184 068 controls derived from 173 
case-control studies, which included 21 genes (28 
polymorphisms). Statistically significant associations 
with VTE were identified for factor V G1691A, factor V 
A4070G, prothrombin G20210A, prothrombin 
G11991A, PAI-1 4G/5G, and alpha-fibrinogen 
Thr312Ala all in Caucasian populations. The work 
supports a genetic aetiology to VTE disease and 
provides reliable risk estimates [4]. 
Marjot et al., identified 26 case-control studies 
investigating 6 polymorphisms in 6 genes and 
included 1 183 cerebral venous thrombosis (CVT) 
cases and 5 189 controls [5]. Statistically significant 
associations with CVT were found for factor V 
Leiden/G1691A and prothrombin/G20210A. After 
iterative analysis controlling for interstudy 
heterogeneity, methylene tetrahydrofolate 
reductase/C677T was also found to be significantly 
associated. Variants in the remaining 3 genes (Janus 
kinase-2, plasminogen activator inhibitor-1, and 
protein Z) were not significantly associated. Ita 
concluded that CVT has a genetic basis. Genes 
involved in the clotting cascade provide a greater level 
of thrombosis risk in the cerebral venous circulation 
compared with its arterial circulation, and a greater 
level of risk exists for adults compared with children 
[5]. 
 Twelve mutations in the CVD genes (MTHFR 
C677T, MTHFR A1298C, PAI-1 4G/5G (SERPINE1), 
FV G1691A (Leiden), FV H1299R (R2), Prothrombin 
G20210A, Factor XIII V34L, β-Fibrinogen -455 G-A, 
GPIIIa L33P (HPA-1), ACE I/D, Apo B R3500Q, and 
Apo E2/E3/E4) in Macedonians were performed.  We 
published association of MTHFR -677, and -1289 
polymorphisms with occlusive artery disease (OAD) 
and deep vein thrombosis (DVT) in Macedonians and 
any association was not found, except for the 
protective association between MTHFR/CA:CC 
diplotype and AOD [6]. Plasma concentration of total 
homocysteine (tHcy) in patients with DVT in 
comparison with healthy respondents was significantly 
increased for normal:normal (CC:AA), normal 
heterozygote (CC:AC), and heterozygote: 
heterozygote (CT:AC) haplotypes [7]. Any association 
of SERPINE1 polymorphisms with OAD, and DVT in 
Macedonians was not found [8].  There are no data on 
Macedonian population about the Factor V Leiden 
(G1691A), Factor V R2 (A4070G), and Prothrombin 
(G20210A) polymorphisms and their possible 
associations with different diseases.  
 The aim of this study was to analyze 
association of Factor V Leiden (G1691A), Factor V R2 
(A4070G), and Prothrombin (G20210A) genetic 
polymorphisms with occlusive artery disease, and 
deep vein thrombosis in Macedonians in order to 
investigate its role as a part of candidate genes in 
different vascular diseases in Macedonians.  
 
 
Мethods 
 
Investigated groups 
The total studied sample consists of 225 
examinees composed of three different groups: 
healthy individuals, patients with occlusive artery 
disease, and patients with deep venous thrombosis.  
 a) Healthy individuals (n=82), 39 female and 
43 male, aged 40.7 ± 11.3 years, born in different 
parts of Macedonia attending Institute for Transfusion 
for blood donation. Inclusion of healthy individuals 
was random, if medical doctor declare their health as 
acceptable (on the basis of medical documentation, 
completed interview, and physical examination). From 
the investigation were excluded individuals with family 
history of blood vessel diseases. 
b) Occlusive artery disease (n=76), 29 female 
and 47 male patients with proved and documented 
myocardial infarct (n=52), brain infarct (n=22), and 
peripheral artery thrombosis (n=2), aged 63.3 ± 9.6 
years hospitalized the Institute of Heart Diseases, 
Faculty of Medicine, and Institute for Transfusion, 
Skopje for outpatient treatment were included.  
c) Deep vein thrombosis (n=67), 45 female 
and 22 male patients (diagnosed by ultrasonography 
and/or venography), aged 57.7 ± 11.8 years attending 
the Institute of Heart Diseases, Faculty of Medicine, 
and Institute for Transfusion, Skopje for outpatient 
treatment were included. 
 All individuals are of Macedonian origin, and 
residents of different geographical areas of the 
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Republic of Macedonia. All patients and healthy 
individuals included in this study signed a written 
consent to participate in the study which was 
approved by the Committee of the Ministry of 
Education and Science from Republic of Macedonia 
(No 13-1672/4-02).  
 
Genomic DNA isolation and storage 
Blood samples were collected after written 
consent and DNA was isolated from peripheral blood 
leukocytes by the phenol-chlorophorm extraction 
method or with BioRobot EZ1 workstation (QIAGEN) 
[9]. The quality and quantity of DNA was analyzed by 
GeneQuant (Pharmacia). Isolated DNA samples were 
stored in Macedonian Human DNA Bank (hDNAMKD) 
[10]. 
 
Typing Methods 
Assay for the identification of Factor V Leiden 
(G1691A), Factor V R2 (A4070G), and Prothrombin 
(G20210A) genetic polymorphism is based on 
polymerase chain reaction (PCR) and reverse-
hybridization with CVD StripAssay (ViennaLab 
Labordiagnostica GmbH, Austria). The procedure 
includes three steps: 1) DNA isolation, 2) PCR 
amplification using biotinylated primers, 3) 
hybridization of amplification products to a test strip 
containing allele-specific oligonucleotide probes 
immobilized as an array of parallel lines. Bound 
biotinylated sequences are detected using 
streptavidin-alkaline phosphatase and colour 
substrates [11]. The assay covers alleles of Factor V 
Leiden (G1691A), Factor V R2 (A4070G), and 
Prothrombin (G20210A). The genotype of a sample is 
determined using the enclosed Collector
 
sheet or 
using the software StripAssay Evaluator, ver. 2.0, 
ViennaLab Diagnostics GmbH. 
 
Statistical Methods 
The population genetics analysis package, 
PyPop, developed by the Biostatistics Core for the 
Workshop [12-14] was used for analysis of the Factor 
V Leiden (G1691A), Factor V R2 (A4070G), and 
Prothrombin (G20210A) data for this report. Allele 
frequencies and expected Hardy Weinberg 
proportions (HWP) for each Factor V Leiden 
(G1691A), Factor V R2 (A4070G), and Prothrombin 
(G20210A) allele were determined [15]. The exact test 
for genotype frequency deviation from HWP was 
calculated using the Arlequin implementation 
accessed via PyPop [16]. Those alleles that did not fit 
HWP were evaluated to determine whether there was 
an excess of homozygotes or heterozygotes, or if any 
particular genotypes were significantly different from 
expected frequencies by the chi square test. The 
Ewens-Watterson homozygozity test of neutrality 
(EWN) [17] with Slatkin's exact p-values (SEPV) [18, 
19] was used to indicate any deviations from the 
hypothesis of neutral selection for each locus. 
Pearson's p-values, crude Odds Ratio (OR) and 
Wald’s 95% confidence interval (CI) were calculated 
for associations' analysis between Factor V Leiden 
(G1691A), Factor V R2 (A4070G), and Prothrombin 
(G20210A) alleles and blood vessel disease with 
GraphPad QuickCalcs: free statistical calculators 
(http://www.graphpad.com/quickcalcs/) with 
Bonferroni corrected p-value [20, 21]. P less than 0.05 
were taken as significant. 
 
 
Results 
 
Factor V, Factor V R2, and Prothrombin 
Alleles and Genotypes 
 
Frequencies of Factor V, Factor V R2, and 
Prothrombin alleles, test of neutrality with Fnd statistic 
(Ewens-Watterson test of neutrality), and Slatkin's 
Exact P value (SEPV) with P of F statistics in 
Macedonians are shown on the Table 1.  
 The frequency of G alleles for Factor V varies 
between 0.976 for healthy participants, 0.954 for 
occlusive artery disease, and 0.948 for deep vein 
thrombosis indicating dominance of this allele.  The 
frequency of A allele is smallest in healthy participants 
(0.024), and is more frequent in patients with deep 
vein thrombosis (0.052), and with occlusive artery 
disease (0.046).  Similar findings were found for 
Factor V R2 alleles (A and G), as well as for 
Prothrombin alleles (G and A). For the all Factor V, 
Factor V R2, and Prothrombin alleles, test of neutrality 
showed positive value for Fnd statistic without 
significant P of F statistics (Table 1).  
Table 1: Frequencies of Factor V, Factor V R2, and 
Prothrombin alleles, test of neutrality with Fnd statistic 
(Ewens-Watterson test of neutrality), and Slatkin's Exact P 
Value with P of F statistics in Macedonians 
 n
*
 
Alleles 
Test of Neutrality (F) 
EWN
†
 SEPV
‡
 
Allele Number Frequency Fnd P of F 
Factor V       
Healthy 82 
G 160 0.976 
0.757 0.671 
A 4 0.024 
Occlusive artery 
disease (OAD) 
76 
G 145 0.954 
0.530 0.552 
A 7 0.046 
Deep vein 
thrombosis (DVT) 
67 
G 127 0.948 
0.487 0.541 
A 7 0.052 
Factor V R2       
Healthy 82 
A 156 0.951 
0.487 0.532 
G 8 0.049 
Occlusive artery 
disease (OAD) 
76 
A 138 0.908 
0.057 0.411 
G 14 0.092 
Deep vein 
thrombosis (DVT) 
67 
A 123 0.918 
0.177 0.447 
G 11 0.082 
Prothrombin       
Healthy 82 
G 160 0.976 
0.757 0.671 
A 4 0.024 
Occlusive artery 
disease (OAD) 
76 
G 149 0.980 
0.824 0.729 
A 3 0.020 
Deep vein 
thrombosis (DVT) 
67 
G 131 0.978 
0.817 0.721 
A 3 0.022 
*
, n= number of participants; 
†
, EWN=Ewens-Watterson test of neutrality; 
‡
, 
SEPV=Slatkin's Exact P Value. 
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Observed versus expected frequency of 
Factor V, Factor V R2, and Prothrombin genotypes, 
Hardy Weinberg proportion (HWP), and Guo and 
Thompson Hardy Weinberg Output (GTHWO) in 
Macedonians is given on the Table 2.  
Table 2:  Observed vs. expected Factor V, Factor V R2, and 
Prothrombin genotypes for each investigated group, Hardy 
Weinberg proportions, and Guo and Thompson Hardy 
Weinberg Output in Macedonians 
Investigated group Genotype 
Observed 
number 
Expected 
number 
P-
value 
HWP
*
 P-
value 
GTHWO
†
 
P-value 
Factor V       
Healthy 
GG 
GA 
AA 
78 (95.1%) 
4 (4.9%) 
0 (0.0%) 
78.0 
3.9 
0.0 
0.996 
& 
& 
0.991 1.000 
Occlusive artery 
disease (OAD) 
GG 
GA 
AA 
69 (92.0%) 
7 (8.0%) 
0 (0.0%) 
69.2 
6.7 
0.2 
0.984 
0.900 
& 
0.969 1.000 
Deep vein 
thrombosis (DVT) 
GG 
GA 
AA 
60 (89.5%) 
7 (10.5%) 
0 (0.0%) 
60.2 
6.6 
0.2 
0.981 
0.887 
& 
0.885 1.000 
Factor V R2       
Healthy 
AA 
AG 
GG 
74 (90.2%) 
8 (9.8%) 
0 (0.0%) 
74.2 
7.6 
0.2 
0.982 
0.887 
& 
0.964 1.000 
Occlusive artery 
disease (OAD) 
AA 
AG 
GG 
64 (84.2%) 
10 (13.1%) 
2 (2.7%) 
62.6 
12.7 
0.6 
0.864 
0.447 
& 
0.436 0.109 
Deep vein 
thrombosis (DVT) 
AA 
AG 
GG 
56 (83.6%) 
11 (16.4%) 
0 (0.0%) 
56.5 
10.1 
0.5 
0.952 
0.776 
& 
0.771 1.000 
Prothrombin       
Healthy 
GG 
GA 
AA 
78 (95.1%) 
4 (4.9%) 
0 (0.0%) 
78.0 
3.9 
0.0 
0.996 
& 
& 
& 1.000 
Occlusive artery 
disease (OAD) 
GG 
GA 
AA 
73 (96.0%) 
3 (4.0%) 
0 (0.0%) 
73.0 
2.9 
0.0 
0.998 
& 
& 
& 1.000 
Deep vein 
thrombosis (DVT) 
GG 
GA 
AA 
64 (95.5%) 
3 (4.5%) 
0 (0.0%) 
64.0 
2.9 
0.0 
0.998 
& 
& 
& 1.000 
*
, HWP = Hardy Weinberg proportions; 
†
, GTHWO = Guo and Thompson Hardy Weinberg 
Output; 
&
, Cannot be calculated because expected 5, 2 test. 
 
The most frequent Factor V genotype in 
healthy participants was GG with observed frequency 
of 95.1%, smaller frequency was found for GA 
genotype (4.9%), and zero (0.0%) frequency was 
found for AA genotype. The frequency of Factor V/GA 
genotype were slightly decreased in patients with 
occlusive artery disease and deep vein thrombosis 
(92.0% and 89.5%, respectively), but Factor V/AA was 
absent (0.0%). Similar results were found for Factor V 
R2 genotypes with the highest observed frequency of 
AA genotype (90.2%) in healthy participants, and 
slightly lower frequency in patients with occlusive 
artery disease (84.2%) and deep vein thrombosis 
(83.6%). Homozygous Factor V R2/GG genotype was 
absent in investigated groups (0.0%), except in 
patients with occlusive artery disease (2.7%).  The 
most frequent genotype of Prothrombin was GG with 
observed frequency of 95.1% in healthy participants, 
95.5% in patients with deep vein thrombosis, and 
96.0% in patients with occlusive artery disease. 
Heterozygous Prothrombin/GA genotype observed 
frequency was found in less than 5% in all 
investigated groups. Homozygous Prothrombin/AA 
genotype was absent in all investigated groups 
(0.0%). P-values and Hardy Weinberg proportions 
were no significant. P-value of Guo and Thompson 
Hardy Weinberg output was 1.000 for all investigated 
genes (Factor V, Factor V R2, and Prothrombin) in all 
investigated groups, except for Factor V R2 in patients 
with occlusive artery disease (0.109) (Table 2). 
  
Association between Factor V, Factor V R2, 
and Prothrombin polymorphisms and blood 
vessels diseases 
 Association between Factor V, Factor V R2, 
and Prothrombin alleles and genotypes with occlusive 
artery disease is shown on the Table III. We did not 
found any significant association between Factor V, 
Factor V R2, and Prothrombin alleles and genotypes 
with occlusive artery disease (Pearson's P value 
greater than 0.05) (Table 3).  
Table 3:  Association between Factor V, Factor V R2, and 
Prothrombin alleles and genotypes with occlusive artery 
disease with Pearson's P-value, crude odds ratio, and Wald’s 
95% confidence interval in Macedonians 
Allele or Genotype 
OAD 
(n=75) 
Healthy (n=82) 
Pearson’s 
P-value 
Odds ratio 
Wald’s 
95% CI
†
 
Factor V      
G 145 (95.4%) 160 (97.6%) 0.294 0.518 0.148-1.805 
A 7 (5.6%) 4 (2.4%) 0.294 1.931 0.554-6.732 
GG 69 (92.0%) 78 (95.1%) 0.285 0.505 0.142-1.801 
GA 7 (8.0%) 4 (4.9%) 0.285 1.978 0.555-7.048 
AA 0 (0.0%) 0 (0.0%) & & & 
Factor V R2      
A 138 (90.8%) 156 (95.1%) 0.130 0.505 0.206-1.241 
G 14 (9.2%) 8 (4.9%) 0.130 1.978 0.806-4.858 
AA 64 (84.2%) 74 (90.2%) 0.254 0.577 0.222-1.498 
AG 10 (13.1%) 8 (9.8%) 0.463 1.445 0.538-3.882 
GG 2 (2.7%) 0 (0.0%) & & & 
Prothrombin      
G 149 (98.0%) 160 (97.6%) 0.779 1.242 0.273-5.640 
A 3 (2.0%) 4 (2.4%) 0.779 0.805 0.177-3.658 
GG 73 (96.0%) 78 (95.1%) 0.776 1.248 0.270-5.766 
GA 3 (4.0%) 4 (4.9%) 0.776 0.801 0.173-3.703 
AA 0 (0.0%) 0 (0.0%) & & & 
*, OAD=occlusive artery disease; 
†
, CI=confidence interval; 
&
, Cannot be calculated 
because expected 5, 2 test.  
 
Association between Factor V, Factor V R2, 
and Prothrombin alleles and genotypes with deep vein 
thrombosis is shown on the Table IV. We did not 
found any significant association between Factor V, 
Factor V R2, and Prothrombin alleles and genotypes 
with deep venous thrombosis (Pearson's P value 
greater than 0.05) (Table 4).  
 
 
Discussion 
 
In this manuscript we report Factor V, Factor 
V R2, and Prothrombin alleles and genotypes that 
exist in Macedonians, and possible association with 
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occlusive artery disease, as well as with deep venous 
thrombosis. The results did not show any significant 
association of Factor V, Factor V R2, and Prothrombin 
alleles and genotypes with occlusive artery disease or 
deep venous thrombosis. 
Table 4:  Association between Factor V, Factor V R2, and 
Prothrombin alleles and genotypes with deep vein thrombosis 
with Pearson's P-value, crude odds ratio, and Wald’s 95% 
confidence interval in Macedonians 
Allele or 
Genotype 
DVT 
(n=66) 
Healthy 
(n=82) 
Pearson’s 
P-value 
Odds ratio 
Wald’s 
95% CI
†
 
Factor V      
G 127 (94.8%) 160 (97.6%) 0.205 0.454 0.130-1.585 
A 7 (5.2%) 4 (2.4%) 0.205 2.205 0.631-7.698 
GG 60 (89.5%) 78 (95.1%) 0.196 0.440 0.123-1.571 
GA 7 (10.5% 4 (4.9%) 0.196 2.275 0.636-8.131 
AA 0 (0.0%) 0 (0.0%) & & & 
Factor V R2      
A 123 (91.8%) 156 (95.1%) 0.242 0.573 0.224-1.469 
G 11 (8.2%) 8 (4.9%) 0.242 1.744 0.681-4.468 
AA 56 (83.6%) 74 (90.2%) 0.225 0.550 0.208-1.459 
AG 11 (16.4%) 8 (9.8%) 0.225 1.817 0.686-4.815 
GG 0 (0.0%) 0 (0.0%) & & & 
Prothrombin      
G 131 (97.8%) 160 (97.6%) 0.910 1.092 0.240-4.965 
A 3 (2.2%) 4 (2.4%) 0.910 0.916 0.201-4.166 
GG 64 (95.5%) 78 (95.1%) 0.908 1.094 0.236-5.068 
GA 3 (4.5%) 4 (4.9%) 0.908 0.914 0.197-4.234 
AA 0 (0.0%) 0 (0.0%) & & & 
*, DVT=deep vein thrombosis; 
†
, CI=confidence interval; 
&
, Cannot be calculated because 
expected 5, 2 test. 
 
We found positive value for Fnd statistic, 
without significant P of F statistics in healthy 
participants and in patients with occlusive artery 
disease and deep venous thrombosis. We found also 
that Factor V, Factor V R2, and Prothrombin 
genotypes are in equilibrium with HWP in healthy 
participants and in patients with OAD, as well as in 
patients with DVT.  
Our results are in accordance with the meta-
analysis published by Keijzer et al., 2007 where 
evidence for interaction between factor V Leiden and 
hyperhomocysteinemia for risk of venous thrombosis 
was not found [3]. Other studies with meta-analysis 
have shown that there is either moderate [1, 2] or 
significant association of several candidate genes with 
venous thromboembolism and cerebral venous 
thrombosis [4, 5]. The differences may be partly 
dependent on the number of investigated controls and 
patients. 
 Diseases of the cardiovascular system are 
complex genetic traits which include hundreds of 
associated candidate genes [22]. The numbers of 
patients and controls of our study is very small: in the 
association studies, there are possibilities that some 
positive results might be spurious and some negative 
findings might be a consequence of low statistical 
power. It could be due to their small sample size or 
methodological shortcomings, such as the selection of 
an appropriate control group. Further studies are 
merited to assess these associations in greater detail 
(including any gene-gene and gene-environment 
interactions) and to determine any implications with 
regard to potential therapies designed to reverse 
patients' prothrombotic phenotype.  
 Compared with patients with both deep 
venous thrombosis and pulmonary embolism, isolated 
deep venous thrombosis patients more often had 
thrombi located distally and had a similar number of 
affected veins. Compared with isolated pulmonary 
embolism patients, isolated deep venous thrombosis 
patients had a similar time between provocation and 
diagnosis, and similar in vitro coagulation time and 
thrombus density. Although some effects were 
differential for FVL-carriers and noncarriers, and some 
were differential for pulmonary embolism and deep 
venous thrombosis patients, none of the potential 
mechanisms offered a clear explanation [23]. Because 
our study groups are heterogeneous, the results 
should be analysed with precaution, and we need 
more homogenous subgroups for definitive conclusion 
about association between SERPINE1 gene and 
cardiovascular diseases 
 In summary, association of Factor V, Factor V 
R2, and Prothrombin polymorphisms with occlusive 
artery disease, and deep venous thrombosis in 
Macedonians was not found. The results can be used 
for population meta-analysis, as well as for 
association studies with different diseases. 
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